title: Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial.
abstract: OBJECTIVE
  To assess the efficacy of lamotrigine, a novel antiepileptic drug that inhibits glutamate release, to retard disease progression in Huntington disease (HD).
  
  
  BACKGROUND
  Excitatory amino acids may cause selective neuronal death in HD, and lamotrigine may inhibit glutamate release in vivo.
  
  
  METHODS
  A double-blinded, placebo-controlled study was conducted of 64 patients with motor signs of less than 5 years' duration who were randomly assigned to either placebo or lamotrigine and assessed at 0 (baseline), 12, 24, and 30 months. The primary response variable was total functional capacity (TFC) score. Secondary response variables included the quantified neurological examination and a set of cognitive and motor tests. Repeated fluorodeoxyglucose measurements of regional cerebral metabolism using PET also were included.
  
  
  RESULTS
  Fifty-five patients (28 on lamotrigine, 27 on placebo) completed the study. Neither the primary response variable nor any of the secondary response variables differed significantly between the treatment groups. Both the lamotrigine and the placebo group deteriorated significantly on the TFC, in the lamotrigine group by 1.89 and the placebo group by 2.11 points. No effect of CAG size on the rate of deterioration could be detected.
  
  
  CONCLUSIONS
  There was no clear evidence that lamotrigine retarded the progression of early Huntington disease over a period of 30 months. However, more patients on lamotrigine reported symptomatic improvement (53.6 versus 14.8%; p = 0.006), and a trend toward decreased chorea was evident in the treated group (p = 0.08). The study also identified various indices of disease progression, including motor tests and PET studies, that were sensitive to deterioration over time.
authors.affiliation: Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada.
authors.forename: B
authors.initials: B
authors.lastname: Kremer
authors.forename: C M
authors.initials: CM
authors.lastname: Clark
authors.forename: E W
authors.initials: EW
authors.lastname: Almqvist
authors.forename: L A
authors.initials: LA
authors.lastname: Raymond
authors.forename: P
authors.initials: P
authors.lastname: Graf
authors.forename: C
authors.initials: C
authors.lastname: Jacova
authors.forename: M
authors.initials: M
authors.lastname: Mezei
authors.forename: M A
authors.initials: MA
authors.lastname: Hardy
authors.forename: B
authors.initials: B
authors.lastname: Snow
authors.forename: W
authors.initials: W
authors.lastname: Martin
authors.forename: M R
authors.initials: MR
authors.lastname: Hayden
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000523:psychology; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D013997:Time Factors; D014055:Tomography, Emission-Computed; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D000927:Anticonvulsants; D014227:Triazines; D000077213:Lamotrigine